跳至主要内容
临床试验/NCT01713478
NCT01713478已完成不适用

An Integrated Approach of Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis: Echocardiography, Specific Biomarkers, and Vascular Assessment

Carol Davila University of Medicine and Pharmacy2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2011年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
试验地点
2
主要终点
Subclinical Myocardial Dysfunction

研究概览

简要总结

The prevalence of hepatic cirrhosis in Romania is very high, with a 10-year mortality of 34-66%. Upward trend of mortality is observed. It is known that cirrhosis is associated with cardiac abnormalities. These can induce several complications of cirrhosis, and increase postoperative mortality. Therefore, it is a major public health issue and research in this field should be a priority.

Few studies evaluated the cardiac function in cirrhotic patients, using only conventional echocardiography. However, this allows only the late diagnosis of cardiac dysfunction, which might be already irreversible. Consequently, description of new parameters, which could detect early dysfunction, becomes essential. There is no study designed to estimate intrinsic myocardial properties in cirrhosis. New methods (Tissue Doppler and Speckle-tracking echocardiography) could be essential to detect early cardiac dysfunction. The exact role of biological markers in the diagnosis of cardiac dysfunction remains to be clarified. Impaired cardiac function coupled with augmented vascular function could be the model for cirrhotic patients. This type of ventriculo-arterial interaction has never been described.

The main objectives of our project are:

  1. to investigate the mechanisms which lead to cardiac dysfunction;
  2. to describe new parameters for the early diagnosis of cirrhotic cardiomyopathy;
  3. to describe the type of ventriculo-arterial interaction;
  4. the association between biological markers and echo parameters.

详细描述

Scientific context and motivation:

Cirrhosis is the end stage of chronic damage to the liver. The prevalence is estimated to be very high in Romania, more than 1000/100.000 inhabitants, with 10-year mortality of 34-66%. Upward trends of mortality are observed in a few countries, including Romania, which had extremely high mortality rates. The cost in terms of hospital costs and lost productivity is high. Therefore, hepatic cirrhosis represents a major public health in Romania.

It is known that hepatic cirrhosis is associated with cardiovascular abnormalities. These abnormalities have been suggested to induce/aggravate several complications of cirrhosis, and also to increase postoperative mortality after major surgery or liver transplantation. Few studies documented the existence of a hyperdynamic circulation, with increased cardiac output and reduced systemic vascular resistance. Despite this hyperkinetic circulation, some patients have abnormal ventricular function unmasked by physiologic/pharmacologic stress.

There are few studies of cardiac function in cirrhosis, although contractile function disorders found in nonalcoholic cirrhosis in animal models suggested that this is independent from alcohol intake. These issues are complicated by the fact that, alcohol use represents one of the commonest causes of both cirrhosis and cardiomyopathy. There are reasons to believe that cirrhosis per se may be associated with subtle contractile dysfunction. First, hyperkinetic circulatory changes may induce a high-output cardiac failure resembling a chronic volume overload of the heart. Second, cirrhosis is associated with high serum catecholamine levels, and long-term exposure to elevated catecholamines results in cardiomyopathy. Third, necropsy series of patients with alcoholic/nonalcoholic cirrhosis show similar cardiac pathologic findings: diffuse fibrosis, subendocardial edema, nuclear and cytoplasmic vacuolation.

Despite the increased cardiac output, ventricular inotropic and chronotropic responses to stimuli are blunted, a condition known as "cirrhotic cardiomyopathy". These include systolic and diastolic dysfunction, electrophysiological changes, and structural changes. There are no clear consensus definition for this condition. Cardiac function was evaluated by classic echocardiography, 2D and color/spectral Doppler: cardiac dimensions, left ventricular ejection fraction (LVEF), systolic and diastolic timings. All of these changes are dependent on load conditions, and cirrhosis has major variability of preload conditions. However, these conventional measurements allow only the late diagnosis of cardiac dysfunction, which might be already irreversible.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with certified diagnosis of hepatic cirrhosis;
  • Age over 18 years;
  • Informed consent signed;
  • Sinus rhythm;
  • Ejection fraction > 50%

排除标准

  • Any history of cardiovascular disease/active cardiovascular treatment(βblockers used for prevention of the variceal hemorrhage will be stopped 24h before the evaluation);
  • Diabetes mellitus;
  • Chronic diseases/neoplasia with estimated survival time under 6 months;
  • Pulmonary diseases that could affect cardiac function;
  • Other etiology of cirrhosis that could affect cardiac function: Wilson disease, hemochromatosis, glycogen storage diseases;
  • Encephalopathy over grade 2/ascitis without medical control;
  • Inappropriate quality of echocardiographic images.

结局指标

主要结局

Subclinical Myocardial Dysfunction

时间窗: Baseline

The main objectives are to detect, by new echocardiographic methods, early cardiac dysfunction in cirrhotic patients

次要结局

  • Biomarkers(Baseline)

研究者

发起方
Carol Davila University of Medicine and Pharmacy
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dragos Vinereanu

Professor, MD, PhD, FESC

Carol Davila University of Medicine and Pharmacy

研究点 (2)

Loading locations...

相似试验

Subclinical Myocardial Dysfunction in Patients With... | 临床试验